COMPASS Pathways plc filings document the regulatory record for a biotechnology company developing COMP360, a proprietary synthetic psilocybin formulation for mental health indications including treatment-resistant depression. Current reports disclose financial results, clinical and regulatory updates, investor presentation materials, and material agreements tied to debt facilities and securities offerings.
Proxy and other filings cover annual general meeting matters, board structure, committee assignments, compensation arrangements, and shareholder voting procedures. Capital-structure disclosures include American Depositary Shares, ordinary shares, pre-funded warrants, registration statement references, underwriting terms, and loan and security agreement amendments.
COMPASS Pathways plc (CMPS) reported a third-quarter 2026 net loss of $9.8 million, compared with $137.7 million a year earlier. The decrease was primarily driven by non-cash fair-value adjustments to warrant liabilities: a $40.8 million gain in the quarter versus a $101.3 million loss in the prior-year quarter. Cash and cash equivalents were $444.0 million at September 30, 2026, and COMPASS expects its cash position to fund operating expenses and capital expenditures into 2028.
The company said the final rolling NDA submission for COMP360 is nearing completion and will be filed in the next two weeks. Launch readiness is on track for an expected first-half 2027 launch, subject to FDA approval. COMPASS reported positive results from two Phase 3 TRD trials; 52-week open-label data from COMP005 showed added benefit from an additional 25 mg dose, with durability extending to one year. A late-stage PTSD trial is ongoing.
Third-quarter research and development expenses were $23.5 million, compared with $27.3 million a year earlier. Selling, general and administrative expenses were $33.0 million, compared with $13.2 million, as the company prepared for potential commercialization. Total debt was $51.0 million at September 30, 2026.
COMPASS Pathways plc (CMPS) reported no product revenue and a $172.4 million net loss for the nine months ended September 30, 2026, versus $194.0 million in 2025. Cash and cash equivalents were $444.0 million as of September 30, 2026; management believes they will fund operating expenses and capital expenditures into 2028, based on assumptions that may prove wrong. Net cash used in operating activities was $139.0 million, compared with $119.5 million for the nine months ended September 30, 2025.
COMPASS's rolling NDA submission for COMP360 in treatment-resistant depression is ongoing; the FDA granted rolling review and issued a National Priority Voucher. In PTSD, the FDA accepted the IND in January 2026, enabling initiation of a Phase 2b/3 trial. Open-label Part C COMP005 results reported a 13-point average MADRS reduction from baseline at week 52 among participants assigned to 25 mg who received an additional dose; among Part C participants receiving 25 mg, 40%-45% were responders and approximately 30% remitters across timepoints in the six weeks after dosing. The amended Hercules loan agreement provides up to $150.0 million, including a $50.0 million term loan funded January 5, 2026, with additional borrowing subject to milestones and specified approval.
For COMPASS Pathways plc (CMPS), BIT Capital GmbH reported beneficial ownership of 8,148,280 ordinary shares, represented by ADSs, as of September 30, 2026; the reported stake was 5.9%. Each ADS represents one ordinary share. BIT Capital reported sole voting and dispositive power over all 8,148,280 shares, with no shared voting or dispositive power, through its investment discretion over portfolios managed under discretionary investment management mandates. The percentage was based on 138,476,822 ordinary shares outstanding as of July 30, 2026.
COMPASS Pathways plc (CMPS) submitted a notice of proposed sales of American Depositary Shares. The filing lists 26,000 ADS to be sold through Fidelity Brokerage Services LLC on 08/10/2026, following a stock option exercise by the issuer. It also reports that Annalisa Jenkins sold 83,771 ADS for $1,149,153.55 on 08/07/2026 during the prior three months.
For COMPASS Pathways plc (CMPS), former director Annalisa Jenkins reported a proposed sale of 83,771 American Depositary Shares, with an aggregate market value of $1,149,152.80 and an approximate sale date of August 7, 2026. The securities were acquired from the issuer on August 7, 2026 through a stock option exercise paid in cash. The notice lists 138,476,822 American Depositary Shares outstanding.
COMPASS Pathways plc Chief Executive Officer Kabir Nath reported an insider transaction involving 5,962 Ordinary Shares on August 3, 2026. These shares were withheld by the issuer at $11.25 per share to satisfy tax withholding obligations upon vesting of restricted share units, rather than sold in the open market. After this tax-withholding disposition, Nath directly holds 361,028 Ordinary Shares, which may be represented by an equal number of American Depositary Shares.
Compass Pathways plc filed an automatic Form S‑3 shelf registration as a well‑known seasoned issuer, enabling flexible primary offerings of an indeterminate amount of ordinary shares (including ADSs), debt securities, warrants, and units, as well as secondary resales. A separate resale prospectus covers the potential resale of up to 10,649,700 ordinary shares or ADSs by named selling security holders, from which Compass will not receive proceeds. As of June 30, 2026, ordinary shares outstanding were 135,722,306, with 23,848,829 pre‑funded warrants outstanding, each exercisable for one ADS at $0.0001 per ADS. The company highlights advanced clinical progress for its COMP360 psilocybin program in treatment‑resistant depression, including positive Phase 3 results, FDA rolling review of its NDA, and award of a National Priority Voucher, and is initiating a Phase 2b/3 trial in PTSD.
Compass Pathways plc reported results for the three and six months ended June 30, 2026 and outlined clinical, regulatory and launch progress for COMP360 psilocybin in treatment-resistant depression (TRD) and PTSD. Two positive Phase 3 TRD trials showed rapid onset and durable benefit through at least 6 months, with 39% of participants in COMP006 and 25% in COMP005 achieving a ≥25% reduction in MADRS at Week 6 and maintaining benefit on average to Week 26. A rolling New Drug Application submission for COMP360 in TRD is underway, with final modules expected in the fourth quarter of 2026 and potential U.S. commercial launch targeted for the first half of 2027, subject to FDA approval and DEA and state rescheduling.
Research and development expenses were $29.2 million in Q2 2026, slightly below Q2 2025, while general and administrative expenses rose to $23.2 million, driven by commercial preparedness. Net loss for Q2 2026 widened to $253.8 million (loss of $1.88 per share), primarily due to a $205.6 million non-cash loss from fair value changes in warrant liabilities. Cash and cash equivalents were $433.3 million and debt $50.7 million as of June 30, 2026, and the company expects its cash to fund operations into 2028.
Compass Pathways plc reported a net loss of $162.6 million for the six months ended June 30, 2026, compared with $56.3 million a year earlier. Results were heavily affected by a $74.7 million year‑to‑date non‑cash loss from fair value changes in warrant liabilities and higher general and administrative spending tied to commercial preparation.
Operating expenses for the six months were $95.3 million, including research and development of $55.7 million and general and administrative of $39.6 million. Cash and cash equivalents grew to $433.3 million from $149.6 million at year‑end, driven by equity offerings, warrant exercises and additional Hercules term debt; the company states this should fund operating and capital needs into 2028.
Total assets were $504.6 million, liabilities $420.0 million and shareholders’ equity improved from a deficit to $84.5 million, despite sizable warrant liabilities of $337.5 million. Clinically, both pivotal Phase 3 TRD trials (COMP005 and COMP006) met primary endpoints with statistically significant, clinically meaningful MADRS reductions, supporting an ongoing rolling NDA review with the FDA and a National Priority Voucher, while a Phase 2b/3 PTSD trial (COMP202) is initiating under an accepted IND.
Compass Pathways reports new 26-week Phase 3 COMP006 data for its COMP360 psilocybin treatment in treatment-resistant depression and outlines an accelerated U.S. approval path. In nearly 600 participants, 39% of those receiving 25 mg achieved a clinically meaningful ≥25% reduction in MADRS scores by Week 6 and on average maintained benefit through at least Week 26, with additional dosing moving some into remission.
Serious adverse events were low and similar between arms over 26 weeks, at 6.3% in the 1 mg arm and 5.7% in the 25 mg arm, and most adverse events were transient on the day of dosing. A rolling NDA submission with the FDA is underway, with final submission expected in Q4 2026 and a potential U.S. launch in the first half of 2027, subject to FDA approval and DEA rescheduling.